NDA 205266 · Sun Pharm
Odomzo
Sonidegib Phosphate · Oral
NovelLast checked: Nov 19, 2026Latest source record: Aug 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jul 24, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
47
1 Phase 3, 4 recruiting
FAERS reports
1,679
819 serious, 157 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY ODOMZO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. ODOMZO is embryotoxic, fetotoxic, and teratogenic in animals [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Verify the pregnancy status of females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during treatment with ODOMZO and for at least 20 months after the last dose [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3) ] . Advise males of the potential risk of exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with ODOMZO and for at least 8 months after the last dose [see Warnings and Precautions (5.1) and Use in Specific Populations (8.3) ] ....
What it is approved for
From the label in effect Dec 31, 2024.
ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ( 1 )
Mechanism: Sonidegib is an inhibitor of the Hh pathway. Sonidegib binds to and inhibits Smoothened, a transmembrane protein involved in Hh signal transduction.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 18, 2017 Supplement 4 · Efficacy LabelLetter
- Jul 24, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
1 products under this application
- ODOMZO · SONIDEGIB PHOSPHATE EQ 200MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sonidegib" as an intervention, any sponsor and status, largest first.
- A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell CarcinomaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01327053 · 230 participants · Start Jun 29, 2011 · Primary completion Jun 28, 2013
Drug: LDE225 · For: Basal Cell Carcinoma
Sites: Fayetteville, Arkansas; Los Angeles, California; Stanford, California · 62 sites in all
JemincareIndustry
NCT06880848 · 160 participants · Start Jun 21, 2023 · Primary completion Aug 26, 2025
Drug: Sonidegib Phosphate Capsules · For: Carcinoma, Basal Cell (BCC)
Sites: Beijing, China
Novartis PharmaceuticalsNovartis (NVS)
NCT01576666 · 120 participants · Start Jul 2012 · Primary completion Apr 2015
Drug: LDE225; BKM120 · For: Dose Escalation; Safety; Preliminary Efficacy and 9 more
Sites: Los Angeles, California; San Francisco, California; Tampa, Florida · 23 sites in all
- Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in PatientsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01769768 · 114 participants · Start Apr 2013 · Primary completion Aug 2016
Drug: LDE225; Wafarin and 1 more · For: Advanced Solid Tumor
Sites: Duarte, California; Kansas City, Kansas; Boston, Massachusetts · 13 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT00880308 · 103 participants · Start Mar 2009 · Primary completion Jul 2013
Drug: LDE225 · For: Advanced Solid Tumor Cancers; Medulloblastoma; Basal Cell Carcinoma
Sites: Pittsburgh, Pennsylvania; San Antonio, Texas; Barcelona, Spain · 5 sites in all
University Hospital, LilleAcademic, hospital or other
NCT05561634 · 82 participants (planned) · Start Jun 20, 2023 · Primary completion Jun 20, 2029
Drug: Vismodegib · For: Basal Cell Carcinoma; Radiotherapy; Complications
Sites: Lille, France
- Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic CancerCompleted
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
NCT02358161 · 78 participants · Start Sep 2015 · Primary completion Sep 2018
Drug: gemcitabine and nab paclitaxel · For: Pancreatic Cancer
Sites: Amsterdam, Netherlands
Novartis PharmaceuticalsNovartis (NVS)
NCT01125800 · 76 participants · Start Feb 2011 · Primary completion Oct 2014
Drug: LDE225 · For: Medulloblastoma; Rhabdomyosarcoma; Neuroblastoma and 3 more
Sites: Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- muscle spasms230
- alopecia136
- fatigue123
- death119
- off label use117
- product use issue96
- nausea90
- product dose omission issue89
- ageusia82
- therapy cessation82
- weight decreased81
- asthenia71
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 12 |
| 2016 | 30 |
| 2017 | 51 |
| 2018 | 59 |
| 2019 | 100 |
| 2020 | 76 |
| 2021 | 95 |
| 2022 | 119 |
| 2023 | 140 |
| 2024 | 473 |
| 2025 | 293 |
| 2026 | 229 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Odomzo (Sonidegib Phosphate)
2024 spending
$46.0M
Beneficiaries
808
3,596 claims
Per beneficiary
$56,947
$446.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $23,572,553 |
| 2021 | $26,758,121 |
| 2022 | $24,443,718 |
| 2023 | $29,330,355 |
| 2024 | $46,013,355 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma.
Casey D, Demko S, Shord S, et al. · Clin Cancer Res 2017 · Randomized Controlled Trial
- Management of Skin Cancer in the High-Risk Patient.
Behan JW, Sutton A, Wysong A · Curr Treat Options Oncol 2016 · Meta-Analysis, Review
- Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y, Song Q, Day BW · Acta Neuropathol Commun 2019 · Meta-Analysis, Systematic Review
- Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.
Cazet AS, Hui MN, Elsworth BL, et al. · Nat Commun 2018 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Safety and Efficacy of Vismodegib and Sonidegib in Advanced Basal Cell Carcinoma of the Head and Neck: A Systematic Review and Meta-Analysis.
Doyle CM, Cevik J, Ramakrishnan A · Head Neck 2026 · Systematic Review, Meta-Analysis
- Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.
Chen L, Aria AB, Silapunt S, et al. · Future Oncol 2018 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Sun Pharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.